



Coordinator

Personal Information*

<i>Name:</i>	François Tison	
<i>Data of birth:</i>	April 19th 1962	
<i>Contact details:</i>	Institut des maladies neurodégénératives CNRS UMR 5293 Université de Bordeaux Bât 3B 1er étage 146 rue Léo Saignat 33076 Bordeaux cedex francois.tison@u-bordeaux.fr Tel: +33 05 57 57 15 40 Fax: +33 05 56 90 14 21	Clinical Branch (IMNc) Hôpital Pellegrin CHU de Bordeaux Place Amélie Raba-Léon 33076 Bordeaux Cedex francois.tison@chu-bordeaux.fr Tel: + 33 5 5782 12 53 Fax: + 33 5 82 13 62

Bio-sketch

François Tison, aged 53 years, is Professor of Neurology at Bordeaux University (BU)-Consultant Neurologist at the University Hospital of Bordeaux (CHU-B) He is head of the Institute of Neurodegenerative Diseases-clinical branch (IMNc, <http://www.imnc-bordeaux.org>), the Memory Clinic (CMRR) and the Motricity Unit at the Department of Clinical Neurology, CHU-B, and adjunct director of the Institute for Neurodegenerative Diseases (IMN, CNRS UMR 5293-<http://www.imn-bordeaux.org>). He conducted his clinical and research career in the field of neurodegenerative diseases particularly on Parkinson's disease (PD) and related disorders. Regarding patient's care, he created the Movement Disorders Unit at the CHU-B in 1998, the reference center for Huntington's Disease pre-symptomatic diagnosis in 1994, the multiple system atrophy (MSA) rare disease reference center in 2003, the Regional and Inter-Regional Expert center for PD in 2011, then together with E. Bezard, head of the IMN-CNRS UMR 5293, he developed the IMNc, from 2008 to its opening in 2014, within the Neurocampus investment program. Regarding his research career he explored several fields of basic, translational, epidemiological and clinical research in PD. He contributed to dopaminergic neurotransmission chemical neuro-anatomy in basal ganglia, developed new animal models of atypical parkinsonism (nigrosstriatal degeneration). He also conducted epidemiological studies on PD and related disorders in population-based cohorts and coordinated as a PI or Co-PI academic (and industry or foundations (MJFF)-sponsored clinical research studies on neuro-pharmacology, physiopathology and biomarkers of PD and AD. Today 30 clinical research studies are running at the IMNc. He also actively contributes to National or European networks and EC-funded programs (F-CRIN, NS-Park, PD genetics networks, E-MSA Study group, E-Rare). He served on several scientific committees of patient's associations (PD, MSA, PSP), societies (French Neurological Society and MDS, as a treasurer of E-MDS). He authored or Co-authored 225 publications, plus 55 as part of a study group, plus 35 textbook chapters (one book edition), H index=42, 6702 citations without self citations, top 10% citation = 9 (2009-14).

Education

YEAR(s)	INSTITUTION AND LOCATION	DEGREE
1979-85	University of Bordeaux2, Medicine(Bordeaux, France)	
1988	University of Bordeaux2 (Bordeaux, France)	DEA (Master) Neurosciences
1989	University of Bordeaux2 (Bordeaux, France)	Univ Diploma Epidemiology
1985-89	University Hospital of Bordeaux (Bordeaux, France)	DES(Certification Neurology)
1990	University of Bordeaux2 (Bordeaux, France)	MD- Neurologist
1990-94	University of Bordeaux 2 and University Hospital (Bordeaux, France)	Assistant Prof. Neurology
1993	University of Bordeaux2 (Bordeaux, France)	PhD Neurosciences
1994	Institute of Neurology- Movement Disorders Unit (London, UK)	Research Fellow
1995-98	University of Bordeaux 2 and University Hospital (Bordeaux, France)	Associate Prof. Neurology
1996	University of Bordeaux 2 (Bordeaux, France)	(HDR) Research Direction
1998	University of Bordeaux 2 and University Hospital (Bordeaux, France)	Professor Neurology

Current Position

Since 2014 Adjunct Director of the “Institut des Maladies Neurodégénératives” (Institute for Neurodegenerative diseases- IMN), CNRS UMR 5293, Université de Bordeaux, France,
 Director “Institut des Maladies Neurodégénératives” (Institute for Neurodegenerative diseases) clinical branch (IMNc), Bordeaux University and University Hospital, France,
 Director of the CMRR (Memory and Alzheimer Clinic) at the IMNc, Bordeaux University Hospital, France,
 Head of the “Unité Motricité-Epilepsié” (Motricity-Epilepsy Unit), Bordeaux University Hospital, France
 Adjunct Director of the “Pôle des Neurosciences Cliniques”(Clinical Neurosciences Dept) Bordeaux University Hospital, France

Past Positions

1998-2014 Head of Neurology Units (incl. Movement Disorders Unit), South Hospital Group (Hôpital Haut-Lévêque), CHU of Bordeaux, Pessac, France
 1998-2006 Team leader of “Nigrostriatal Degeneration Team » former CNRS UMR5227 Lab (Pr B Bioulac), University of Bordeaux2, Bordeaux, France
 1998-2006 Regional then inter-regional coordinator of the Neurology training diploma (DES)
 2003-2012 Co-director (with Pr Rascol, Toulouse) of the rare disease program French Reference Centre for Multiple System Atrophy. CHU of Bordeaux, Bordeaux, France
 2005-2009 Vice president du Medical Consultative Committee of the South Hospital Group, CHU of Bordeaux, Pessac, France
 2007-2014 Elected Member of the Scientific Council, University of Bordeaux2, Bordeaux
 2011-2014 Director of the Parkinson’s Regional and Inter-regional Expert Centre, CHU of Bordeaux, Bordeaux, France
 Since 2012 Co-direction the University Diploma of Neurodegenerative Disease, University of Bordeaux

Consulting / Scientific Boards and committees

Drug Development Expert for Movement Disorders for several drug companies.
 Past Member of scientific advisory board at French patient’s associations: France Parkinson, PSP France and Association Française du Syndrome des Jambes sans Repos (RLS).
 Past member of the Scientific Council of the Société Française de Neurologie
 Past member of the Scientific Council of “Club des Mouvement anormaux”
 Member of the Local Organizing Committee of the Journées de Neurologie de Langue Française, 2008
 Member of Local Organizing Committee of the 13th International Congress of Parkinson's Disease and Movement Disorders, Paris (2009)
 Co-organizer of the International Symposium on Future Treatment Avenues in Parkinson’s disease (and Related Disorders), Bordeaux (2010 and 2013)
 Founding member of the “Maison du Cerveau”, Bordeaux (2012)

Professional Memberships

Member Société Française de Neurologie
 Member, Société des Neurosciences (France)
 Member, Club des Ganglions de la Base and Club des Mouvements Anormaux (France) and
 Member, Movement Disorders Society (USA), served as Treasurer of the European Section
 Member, American Academy of Neurology

Key bibliometric numbers

h index = 42, g index = 73, 6716 citations without self citations, top 10% citation = 9 (2009-14).

Publications**A. Personal publication (n=226)**

1. Tison F., Orgogozo J.M. **Ophtalmoplégie internucléaire antérieure après angiographie par cathétérisme.** *La Presse Médicale*, 1987 ; 16 : 1332-1333.
2. Tison F., Louiset P., Puymirat E. **Maladie de Marchiafava-Bignami.** *Semaine des Hôpitaux de Paris*, 1988 ; 22 : 1519-1524
3. Tison F., Brochet B., Henry P., Deleplanque B., Mazaux J.M. **Scélrose en plaques aiguë pseudo-vasculaire : une urgence neurologique inhabituelle.** *Annales de Médecine Interne*, 1989 ; 140 : 235.
4. Tison F., Arne P., Henry P. **Myoclonus and adult coeliac disease.** *Journal of Neurology*, 1989 ; 236 : 307-308.
5. Mons N., Tison F., Geffard M. **Identification of L-DOPA-Dopamine and L-DOPA cell bodies in the rat mesencephalic dopaminergic cell systems.** *Synapse (USA)*, 1989 ; 4 : 95-105.
6. Tison F., Mons N., Rouet-Karama S., Geffard M., Henry P. **Endogenous L-Dopa in the rat dorso-vagal complex : an immunocytochemical study by light and electron microscopy.** *Brain Research*, 1989 ; 497 : 260-270.
7. Ferrer X., Julien J., Vital C., Lagueny A., Tison F. **La chorée-acanthocytose.** *Revue Neurologique*, 1990 ; 146 : 732-745.
8. Mons N., Tison F., Geffard M. **Existence of L-DOPA immunoreactive neurons in the rat preoptic region and anterior hypothalamus.** *Neuroendocrinology*, 1990 ; 50 : 425-428
9. Tison F., Mons N., Geffard M. **Immunohistochemistry of endogenous L-Dopa in the rat posterior hypothalamus.** *Histochemistry*, 1990 ; 93 : 655-660.
10. Tison F., Geffard M., Henry P. **Tryptamine is found closely associated to the serotonergic pathways when using an immunohistochemical method of detection in the rat central nervous system.** *Biogenic Amines*, 1990 ; 7 : 235-248.
11. Le Moine C., Tison F., Bloch B. **D2 Dopamine receptor gene expression by cholinergic neurons of the rat striatum.** *Neuroscience Letters*, 1990 ; 117 : 248-252.
12. Tison F., Ferrer X., Julien J. **Delayed onset dystonia and choreoathetosis following centro-pontine myelinolysis.** *Movement Disorders*, 1991 ; 6 : 171-173.
13. Tison F., Mons N., Geffard M., Henry P. **The metabolism of exogenous L-Dopa in the brain : an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain.** *Journal of Neural Transmission* , 1991 ; 311 : 27-39.
14. Tison F., Normand E., Jaber M., Aubert I., Bloch B. **Aromatic-L aminoacid decarboxylase (Dopa-decarboxylase) gene expression in dopaminergic and serotonergic neurons of the rat brain.** *Neuroscience Letters*, 1991 ; 127 : 203-206.
15. Tison F., Louvet-Giendaj C., Henry P., Lagueny A., Gaujard E. **Permanent bruxism as a manifestation of the oculo-facial syndrome related to Whipple's disease.** *Movement Disorders*, 1992 ; 7 : 82-85.
16. Tison F., Duché B., Loiseau P. **Syndrome hémi-parkinsonien vasculaire.** *Revue Neurologique*, 1993 ; 10 : 565-567.
17. Coquet M., Degoul F., Vital A., Malgat M., Mazat J.P., Louvet-Giendaj C., Fontan D., Tison F., Diry M., Marsac C. **MERRF family with 8344 mutation in tRNA(lys). Evidence of a mitochondrial vasculopathy in muscle biopsies.** *Neuromuscular Disorders*, 1993 ; 3 : 593-597.
18. Tison F., Coutelle C., Henry P., Cassaigne A. **Glutathion S-transferase (class mu) phenotype in Parkinson's disease.** *Movement Disorders*, 1994 ; 9 : 117-118.

19. Tison F., Fouillet N., Loiseau P. **Hemiparkinsonism-hemihypertrophy.** *Journal of Neurology*, 1994 ; 241 : 347-348.
20. Tison F., Fouillet N., Henry P. **Apomorphine induce blood glucose concentrations in Parkinson's disease.** *Clinical Neuropharmacology*, 1994 ; 17 : 92-95.
21. Jaber M., Tison F., Fournier M.C., Bloch B. **Differential influence of haloperidol and sulpiride on gene expression in the rat striatum and pituitary.** *Molecular Brain Research*, 1994 ; 23 : 14-20.
22. Tison F., Normand E., Bloch B. **Prenatal ontogeny of D2 dopamine receptor and dopamine transporter mRNA expression in the rat mesencephalon.** *Neuroscience Letters*, 1994 ; 166 : 48-50.
23. Rouanet F., Tison F., Dousset V., Corand V., Orgogozo JM. **Early T2-hypointense abnormalities preceding clinical signs in centro-pontine myelinolysis.** *Neurology*, 1994 ; 44 : 979-980.
24. Tison F., Dartigues J.F., Dubes L., Zuber M., Alperovitch A. Henry P. **Parkinson's disease in an elderly French population : prevalence related to age.** *Acta Neurologica Scandinavica*, 1994 ; 90 : 111-115.
25. Berger E., Tison F., Henry P. **Manifestations cérébrovasculaires des endocardites non bactériennes thrombosantes : intérêt de l'échocardiographie trans-oesophagienne.** *Revue de Médecine Interne*, 1994 ; 15 : 406-408.
26. Tison F., Dartigues J.F., Auriacombe S., Letenneur L., Boller F., Alperovitch A. **Dementia in Parkinson's disease : a population based study in ambulatory and institutionalized individuals.** *Neurology*, 1995 ; 45 : 705-708.
27. Tison F., Wenning G.K., Quinn N.P. **REM-sleep behavior disorder as the presenting symptom of multiple system atrophy.** *Journal of Neurology Neurosurgery and Psychiatry*, 1995 ; 58 : 379-380.
28. Tison F., Wenning G.K., Daniel S.E., Quinn N.P. **Atrophie multisystématisée avec corps de Lewy.** *Revue Neurologique*, 1995 ; 151 : 398-403.
29. Tison F., Boulan P. **An unusual sciatic neuropathy.** *Journal of Neurology Neurosurgery and Psychiatry*, 1995 ; 59 : 16.
30. Tison F., Boulan P., Le Bail B., Cathry-Thomas I., Ragnaud J.M., Henry P. **Encéphalopathie et maladie des griffes du chat.** *La Presse Médicale*, 1995 ; 24 : 1664.
31. Tison F., Wenning G.K., Daniel S.E., Quinn N.P. **The pathophysiology of parkinsonism in multiple system atrophy.** *European Journal of Neurology*, 1995 ; 2 : 435-444.
32. Tison F., Wenning G.K., Volonte M.A., Poewe W.R., Henry P., Quinn N.P. **Pain in multiple system atrophy.** *Journal of Neurology*, 1996 ; 243 : 153-156.
33. Wenning G.K., Tison F., Elliott L., Quinn N.P., Daniel S.E. **Olivopontocerebellar pathology in multiple system atrophy.** *Movement Disorders*, 1996 ; 11 : 157-162.
34. Tison F., Letenneur L., Djossou F., Dartigues J.F. **Further evidence of increased risk of mortality for Parkinson's disease.** *Journal of Neurology Neurosurgery and Psychiatry*, 1996 ; 60 : 592-593.
35. Tison F., Wiart L., Gatterie M., Fouillet N., Lozano V., Henry P., Barat M. **Effects of central dopaminergic stimulation by apomorphine on swallowing disorders of Parkinson's disease.** *Movement Disorders*, 1996 ; 11 : 729-732.
36. O'Connell MT., Tison F., Quinn N.P., Patsalos P.N. **Clinical drug monitoring by microdialysis : application to levodopa therapy in Parkinson's disease.** *British Journal of Clinical Pharmacology*, 1996 ; 42 : 765-769.
37. Tison F., Rouanet F., Neau-Cransac M., Carles J., Couzigou P. **Outcome of liver transplantation in Wilson's disease.** *Parkinsonism and Related Disorders*, 1996 ; 2 : 131-135.
38. Ben-Shlomo Y., Wenning G.K., Tison F., Quinn N.P. **Survival of patients with pathologically-proven multiple system atrophy : a meta-analysis.** *Neurology*, 1996 ; 48 : 384-393.

39. Boraud T., Tison F., Gross C. **Quantification of akinesia in Parkinson's disease : correlations between the tapping test and single joint ballistic movement parameters.** *Parkinsonism and Related Disorders*, 1997 ; 4 : 47-50.
40. Wenning G.K., Tison F., Ben-Shlomo Y., Daniel S.E., Quinn N.P. **Multiple system atrophy : a meta-analysis of 203 pathologically proven cases.** *Movement Disorders*, 1997 ; 12 : 133-147.
41. Tison F., Barberger-Gateau P., Dubroca B., Henry P., Dartigues J.F. **Dependency in Parkinson's disease : a population based survey in non-demented elderly subjects.** *Movement Disorders*, 1997 ; 12 : 910-915.
42. Ballan G., Tison F. **A historical case of probable corticobasal degeneration.** *Movement Disorders*, 1997 ; 12 ; 1073-1074.
43. Boralevi F., Leaute-Labreze C., Tison F., Bioulac-Sage P., Vital C., Delbrel X., Cony M., Geniaux M. **Langerhans-cell histiocytosis and Erdheim-Chester disease: probably not a fortuitous association.** *Annals of Dermatology and Venereology*. 1998 ; 125 : 335-8.
44. Tison F. **Other causes of parkinsonism.** *Baillieres Clinical Neurology*. 1997 ; 6 :205-18.
45. Ballan G., Tison F., Dousset V., Vidailhet M., Agid Y., Henry P. **Etude de l'atrophie corticale par imagerie par résonance magnétique dans la dégénérescence corticobasale.** *Revue Neurologique* , 1998 ; 154: 224-227.
46. Tison F., Arné P., Dousset V., Paty J., Henry P. **Myoclonies propriospinales déclenchées par la relaxation et le sommeil.** *Revue Neurologique*, 1998 ; 154 : 423-425.
47. Dousset V., Tison F., Vital A., Henry P. **Leucodystrophie orthochromatique de l'adulte d'évolution rapide.** *Revue Neurologique*, 1999 ; 153: 234-237.
48. Lagueny A., Tison F., Burbaud P., Le Masson G., Kien P. **Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinium toxin type A.** *Movement Disorders*, 1999 ; 14: 182-185
49. Sibon I., Rajabally Y., Tison F. **Parkinsonism due to a giant aneurysm.** *Movement Disorders*, 1999 ; 14: 99-101
50. Tison F., Lecaroz J., Letenneur L., Dartigues J.F. **Parkinsonism and exposure to neuroleptic drugs in elderly people living in institutions.** *Clinical Neuropharmacology*, 1999 ; 22, 5-10.
51. Vital C., Bioulac-Sage P., Tison F., Rivel J., Begueret H., Gomez C., Leaute-Labreze C., Diard F., Vital A. **Brain infiltration by mixed Langerhans cell histiocytosis and Chester-Erdheim disease: more than just an isolated case ?** *Clinical and Experimental Pathology*, 1999,47:71-76.
52. Ducros A., Denier C., Joutel A., Vahedi K., Michel A., Darcel F., Madigard M., Guerouaou D., Tison F. et al. **Recurrence of the T66M calcium channel gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia.** *American Journal of Human Genetics*, 1999 ; 64 : 89-98.
53. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul, Ladure P., Rascol O., Gross C.E. **Effect of the alpha2 adrenoreceptor antagonist, idazoxan, on the motor disabilities in MPTP-treated monkey.** *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 1999 ; 23: 1237-1246.
54. Tison F., Yekhle F., Chrysostome V., Sourgen C. **Prevalence of multiple system atrophy.** *Lancet*, 2000; 355: 495-496.
55. Scherfler C., Puschban Z., Ghorayeb I., Goebel G.R., Weiler B., Tison F., Poewe W., Wenning G.K. **Complex motor disturbance in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy).** *Neuroscience*, 2000; 26: 43-54.
56. Wenning G.K, Tison F., Scherfler C., Puschban Z., Waldner R., Granata R., Ghorayeb I., Poewe W. **Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis and preliminary experimental evidence.** *Cell Transplantation*, 2000 ; 9: 279-288.
57. Ghorayeb I., Fernagut P.O., Aubert I., Bezard E., Poewe W., Wenning G.K., Tison F. **Towards a primate model of L-Dopa unresponsive parkinsonism mimicking striatonigral degeneration type.** *Movement Disorders*, 2000 ; 15: 531-536.

58. Tison F. **Les échelles d'évaluation dans la maladie de Parkinson.** *Revue Neurologique*, 2000; 156 (Suppl 2Bis): 76-80.
59. Yekhlef F., Ballan G., Macia F., Sourgen C., Tison F. **The value of the pontine MRI "cross sign" in multiple system atrophy.** *Neurology*, 2000, 55: 1239-40
60. Tison F., Arne P., Sourgen C., Chrysostome V., Yekhlef F. **The value of external anal sphincter electromyography for the diagnostic of multiple system atrophy.** *Movement Disorders*, 2000,15: 1148-57.
61. Ghorayeb I., Puschban Z., Fernagut P.O., Scherfler C., Rouland R., Wenning G.K., Tison F. **Simultaneous intra-striatal 6-OHDA and QA injection: a model of early stage striatonigral degeneration (multiple system atrophy).** *Experimental Neurology*, 2001, 167: 133-147.
62. Macia F., Yekhlef F., Ballan G., Delmer O., Tison F. **T2-hyperintense lateral rim and hypointense putamen are typical but not exclusive of multiple system atrophy.** *Archives of Neurology*, 2001, 58: 1024-1026.
63. Danek A., Tison F., Rubio J., Oechsner M., Kalckreuth W., Monaco A.P. **The chorea of McLeod syndrome.** *Movement Disorders*, 2001, 16: 882-889.
64. Apartis E., Tison F., Arne P., Jedynak C.P., Vidailhet M. **Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor.** *Movement Disorders*, 2001, 16: 1133-1136.
65. Danek A., Rubio J.P., Rampoldi L., Ho M., Dobson-Stone C., Tison F., Symmans W.A., Oechsner M., Kalckreuth W., Watt J.M., Corbett A.J., Hamdalla H.H., Marshall A.G., Sutton I., Dotti M.T., Malandrini A., Walker R.H., Daniels G., Monaco A.P. **McLeod neuroacanthocytosis: genotype and phenotype.** *Annals of Neurology*, 2001, 50: 755-764.
66. Perret J, Bourrin JC, Chedru F, Carpentier F, Davous P, Hinault P, Warter JM, Boisson D, Solignac M, David JP, Dien J, Dupuy D, Emile J, Fischer G, Galletti P, Honorat A, Kopp M, Le Guyader J, Maupetit J, Oriol JM, Deseilligny CP, Prince P, Benabid A, Bleton JP, Blond S, Bonnet AM, Broussolle P, Cesaro P, Chaperon J, Damier P, Defer G, Destee A, Fenelon G, N'guyen JP, Pelissier J, Pollak P, Rascol O, Tison F. Tranchant C, Viallet F, Vidailhet M, Ziegler M, Marion MH, Brefel-Courbon C, Derkinderen P, Gayraud D, Krystowiak P, Simon O, Thobois S, Vercueil L **Parkinson's disease: Diagnostic and therapeutic criteria.** *Presse Médicale*, 2001 ; 30 : 379-385
67. Fernagut P.O., Diguët E., Labattu B., Tison F. **A simple method to measure stride length as an index of nigrostriatal dysfunction in mice.** *Journal of Neurosciences Methods*, 2002, 113 : 123-130.
68. Goizet C., Catargi B., Tison F., Tullio-Pelet A., Hadj-Rabia S., Pujol F., Laguëny A., Lyonnet S., Lacombe D. **Progressive bulbospinal amyotrophy in triple A syndrome with AAAS gene mutation.** *Neurology*, 2002, 58: 962-965.
69. Auquier P., Sapin C., Ziegler M., Tison F., Destee A., Dubois B., Allicar M.P., Thibault J.L., Jenkinson C., Peto V. **[Validation of the French language version of the Parkinson's Disease Questionnaire - PDQ-39].** *Revue Neurologique (Paris)*, 2002, 158: 41-50.
70. Wenning G.K., Seppi K., Tison F., Jellinger K. **A novel grading scale for striatonigral degeneration (multiple system atrophy).** *Journal of Neural Transmission*, 2002, 109: 307-320.
71. Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F. **Sleep disorders and their determinants in multiple system atrophy.** *Journal of Neurology Neurosurgery and Psychiatry*, 2002, 72: 798-800.
72. Fernagut P.O., Diguët E., Jaber M., Bioulac B., Tison F. **Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage.** *European Journal of Neuroscience*, 2002, 15: 2053-2056.
73. Tison F., Yekhlef F., Chrysostome V., Balestre E., Quinn N.P., Poewe W., Wenning G.K. **Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.** *Movement Disorders*, 2002, 17: 701-709.
74. Laguëny A., Burbaud P., Dubos J.L., Le Masson G., Guelh D., Macia F., Debras C., Tison F. **Freezing of shoulder flexion impeding boule throwing: a form of task-specific focal dystonia in petanque players.** *Movement Disorders*, 2002, 17: 1092-1095.

75. Fernagut P.O., Diguët E., Stefanova N., Biran M., Wenning G.K., Canioni P., Bioulac B., Tison F. **Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation.** *Neuroscience*, 2002, 114: 1005-1017.
76. Ghorayeb I., Fernagut P.O., Hervier L., Labattu B., Bioulac B., Tison F. **A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis.** *Neuroscience*, 2002, 115: 533-546.
77. Ghorayeb I., Fernagut P.O., Stefanova N., Wenning G.K., Bioulac B., Tison F. **Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.** *Neuroscience Letters*, 2002, 335: 34-38.
78. Tison F., Yekhlef F., Balestre E., Chrysostome V., Quinn N., Wenning G.K., Poewe W. **Application of the International Cooperative Ataxia Scale rating in multiple system atrophy.** *Movement Disorders*, 2002, 17: 1248-1254.
79. Fenelon G., Thobois S., Bonnet A.M., Broussolle E., Tison F. **Tactile hallucinations in Parkinson's disease.** *Journal of Neurology*, 2002, 249: 1699-1703.
80. Yekhlef F., Ballan G., Macia F., Delmer O., Sourgen C., Tison F. **Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD.** *Journal of Neural Transmission*, 2003, 110: 151-169.
81. Fernagut P.O., Chalon S., Diguët E., Guilloteau D., Tison F., Jaber M. **Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice.** *Neuroscience*, 2003, 116 : 1123-1130.
82. Macia F., Ballan G., Yekhlef F., Delmer O., Vital C., Lagueny A., Tison F. **Paralysie supranucléaire progressive: manifestations cliniques et histoire naturelle** *Revue Neurologique (Paris)*, 2003, 159: 31-42.
83. Chrysostome V., Tison F. **Epidemiologie des syndromes parkinsoniens.** *Revue Neurologique (Paris)*, 2003, 159: 343-352.
84. Stefanova N., Puschban Z., Fernagut P.O., Brouillet E., Tison F., Reindl M., Jellinger K.A., Poewe W., Wenning G.K. **Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).** *Acta Neuropathologica (Berl)*, 2003, 106: 157-166.
85. Tison F. **Critères diagnostiques des syndromes parkinsoniens.** *Revue Neurologique (Paris)*, 2003, 159: 3S19-23.
86. Baldi I., Cantagrel A., Lebailly P., Tison F., Dubroca B., Chrysostome V., Dartigues J.F., Brochard P. **Association between Parkinson's disease and exposure to pesticides in southwestern France.** *Neuroepidemiology*, 2003, 22: 305-310.
87. Wenning G.K., Geser F., Stampfer-Kountchev M., Tison F. **Multiple system atrophy: an update.** *Movement Disorders*, 2003, 18: S34-42.
88. Diguët E., Rouland R., Tison F. **Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.** *Annals of Neurology*, 2003, 54:841-2.
89. Guehl D, Tison F., Cuny E, Benazzouz A, Rougier A, Bioulac B, et al. **Complications and adverse effects of deep brain stimulation in Parkinson's patients.** *Expert Review and Neurotherapeutics*, 2003;3:811-19.
90. Diguët E, Gross CE, Bezard E, Tison F., Stefanova N, Wenning GK. **Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.** *Neurology*, 2004, 13:158; *author reply* 158-9
91. Fernagut P.O., Diguët E., Bioulac B., Tison F. **MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration.** *Experimental Neurology*, 2004,185:47-62.
92. Ghorayeb I, Bioulac B, Tison F. **Relationship between stridor and sleep apnoea syndrome: is it as simple as that?** *Journal of Neurology Neurosurgery and Psychiatry*, 2004, 5:512-513.
93. Sibon I, Tison F. **Vascular parkinsonism.** *Current Opinion in Neurology*, 2004, 17: 49-54.

94. Macia F, Perlemoine C, Coman I, Guehl D, Burbaud P, Cuny E, Gin H, Rigalleau V, Tison F. **Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.** *Movement Disorders*, 2004, 19, 106-212
95. Sibon I, Guyot M, Allard M, Tison F. **Parkinsonism following anterior choroidal artery stroke.** *European Journal of Neurology*. 2004 ;11:283-4.
96. Diguët E, Fernagut PO, Normand E, Centelles L, Mülle C, Tison F. **Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history.** *Neurobiology of Disease*, 2004;15:667-75.
97. Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. **Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).** *Neurobiology of Disease*, 2004;15:630-9
98. Sibon I, Fenelon G, Quinn NP, Tison F. **Vascular parkinsonism.** *Journal of Neurology*, 2004;251:513-24.
99. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, Durif F, Bourdeix I. **Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. ?** *Journal of Neurology Neurosurgery and Psychiatry*, 2004;75:689-95.
100. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. **Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.** *Trends in Pharmacological Sciences*, 2004,5:249-53
101. Diguët E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. **Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.** *European Journal of Neurosciences*, 2004;19:3266-76.
102. Chysostome V, Tison F, Yekhlief F, Sourgen C, Baldi I, Dartigues JF. **Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France.** *Neuroepidemiology*, 2004 ;23:201-8.
103. Sibon I, Ghorayeb I, Arne P, Tison F. **Distressing belching and neuroacanthocytosis.** *Movement Disorders*, 2004;19:856-9.
104. Diguët E, Gross CE, Tison F, Bezard E **Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.** *Experimental Neurology*. 2004 ;189:1-4.
105. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A **Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.** *Lancet*, 2004 ;364:1169-71.
106. Sibon I, Macia F, Vital A, Delacourte A, Tison F. **Hypertension and progressive supranuclear palsy: is everything so clear?** *Movement Disorders*, 2004;19:1259-61
107. Krim E, Vital A, Macia F, Yekhlief F, Tison F. **Atypical parkinsonism combining alpha-synuclein inclusions and polyglucosan body disease.** *Movement Disorders*. 2004 20;20:200-204 Erratum: *Movement Disorders*, 2004 29;20:263-264
108. Stefanova N, Mitschnigg M, Ghorayeb I, Diguët E, Geser F, Tison F, Poewe W, Wenning GK. **Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration.** *Journal of Neuroscience Research*, 2004;78:87-91.
109. Wenning GK*, Tison F*, Seppi K, Sampaio C, Diem A, Yekhlief F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W. **Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).** *Movement Disorders*, 2004;19:1391-402.* co-first authors
110. Seppi K, Yekhlief F, Diem A, Luginger Wolf E, Mueller J, Tison F, Quinn NP, Poewe W, Wenning GK. **Progression of parkinsonism in multiple system atrophy.** *Journal of Neurology*, 2005;252:91-6.
111. Perlemoine C, Macia F, Tison F, Coman I, Guehl D, Burbaud P, Cuny E, Baillet L, Gin H, Rigalleau V ; **Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease.** *British Journal of Nutrition*, 2005 ;9:191-8.

112. Ghorayeb I, Provini F, Bioulac B, Tison F. **Unusual nocturnal motor restlessness in a patient with spinocerebellar ataxia 3**. *Movement Disorders*, 2005 29:899-901
113. Diguët E, Fernagut PO, Scherfler C, Wenning G, Tison F. **Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice**. *Journal of Neural Transmission*, 2005;112:613-31
114. Ghorayeb I, Yekhlief F, Bioulac B, Tison F. **Continuous positive airway pressure in multiple system atrophy patients: long term acceptance**. *Sleep Medicine*, 2005 ;6:359-62
115. Foubert-Samier A, Sibon I, Maire C, Tison F. **Long-term cure of tolosa-hunt syndrome after low-dose focal radiotherapy**. *Headache*, 2005; 45:389-91.
116. Tison F, Ghorayeb I **Maladie de Parkinson : troubles associés**. *Revue du Praticien*, 2005;55:741-7
117. Biancalana V, Toft M, Leber I, Tison F, Scherrer E, Thibodeau S, Mandel JL, Brice A, Farrer MJ, Durr A **FMRI premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy**. *Archives of Neurology*, 2005; 62:962-6.
118. Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlief F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, Del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; on behalf of the EMSA-SG. **The European Multiple System Atrophy-Study Group (EMSA-SG)**. *Journal of Neural Transmission*, 2005; 112:1677-1686.
119. Ghorayeb I, Bezard E, Fernagut PO, Bioulac B, Tison F. **Modèles animaux des syndromes parkinsoniens** *Revue Neurologique (Paris)*, 2005;161:907-15
120. Guehl D, Dehail P, de Seze MP, Cuny E, Faux P, Tison F, Barat M, Bioulac B, Burbaud P. **Evolution of postural stability after subthalamic nucleus stimulation in Parkinson's disease: a combined clinical and posturometric study**. *Experimental Brain Research*, 2005 ;19:1-10
121. Barriere G, Cazalets JR, Bioulac B, Tison F, Ghorayeb I. **The restless legs syndrome**. *Progress in Neurobiology*, 2005 ; 77:139-65
122. Scherfler C, Sather T, Diguët E, Stefanova N, Puschban Z, Tison F, Poewe W, Wenning GK. **Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)**. *Journal of Neural Transmission*, 2005;112:1025-33
123. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, Durr A, Brice A; French **Parkinson's Disease Genetics Study Group**. **G2019S LRRK2 mutation in French and North African families with Parkinson's disease**. *Annals of Neurology*, 2005 ; 58:784-7.
124. Fernagut PO, Ghorayeb I, Diguët E, Tison F. **In vivo models of multiple system atrophy**. *Movement Disorders*, 2005 ; 20 Suppl 12:S57-63.
125. Ghorayeb I, Bioulac B, Tison F. **Sleep disorders in multiple system atrophy**. *Journal of Neural Transmission*, 2005 ;112:1669-1675.
126. Guehl D, Cuny E, Benazzouz A, Rougier A, Tison F, Machado S, Grabot D, Gross C, Bioulac B, Burbaud P. **Side-effects of subthalamic stimulation in Parkinson's disease: clinical evolution and predictive factors**. *European Journal of Neurology* 2006; 13:963-71.
127. Tison F, Yekhlief F, Chrysostome V. **Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson's disease**. *Movement Disorders*, 2006;21:1056-7.
128. Corcuff JB, Krim E, Tison F, Foubert-Samier A, Guehl D, Burbaud P, Cuny E, Baillet L, Gin H, Rigalleau V, Perlemoine C. **Subthalamic nucleus stimulation in patients with Parkinson's disease does not increase serum ghrelin levels**. *British Journal of Nutrition*, 2006; 95:1028-9.

129. Guehl D, Dehail P, de Sèze MP, Cuny E, Faux P, Tison F, Barat M, Bioulac B, Burbaud P. **Evolution of postural stability after subthalamic nucleus stimulation in Parkinson's disease: a combined clinical and posturometric study.** *Experimental Brain Research*, 2006;17:206-15.
130. Walker RH, Danek A, Dobson-Stone C, Guerrini R, Jung HH, Lafontaine AL, Rampoldi L, Tison F, Andermann E. **Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes.** *Movement Disorders*, 2006; 21:1794-805.
131. Tison F. **La douleur dans la maladie de Parkinson.** *Revue Neurologique (Paris)*, 2007; 163:15-17
132. RH, Jung HH, Tison F, Lee S, Danek A. **Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome.** *Movement Disorders*, 2007; 22:244-8.
133. Walker RH, Jung HH, Dobson-Stone C, Rampoldi L, Sano A, Tison F, Danek A. **Neurologic phenotypes associated with acanthocytosis.** *Neurology*, 2007; 68:92-8.
134. Guehl D, Cuny E, Tison F, Benazzouz A, Bardinet E, Sibon Y, Ghorayeb I, Yelnick J, Rougier A, Bioulac B, Burbaud P. **Deep brain pallidal stimulation for movement disorders in neuroacanthocytosis.** *Neurology*, 2007;68:160-1.
135. Krim E, Yekhlef F, Chrysostome V, Ghorayeb I, Tison F. **Facteurs pronostiques dans l'atrophie multisystématisée, Cohorte MSA-Aquitaine** *Revue Neurologique (Paris)*, 2007; 163:54-65.
136. Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group, Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rascol O, Tison F, Tranchant C, Vérin M. **LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.** *Archives of Neurology*, 2007; 64:425-30.
137. Crochard A, El Hasnaoui A, Pouchain D, Huas D, Arnulf I, Krieger J, Lainey E, Le Jeune P, Leger D, Schuck S, Texier N, Tison F, Montplaisir J. **Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study.** *Movement Disorders*, 2007 ;22:791-7.
138. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F. **A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France.** *Movement Disorders*, 2007; 22 :1567-72.
139. Lesage S, Lohmann E, Tison F, Durif F, Durr A, Brice A. **Rare heterozygous parkin variants in French early-onset Parkinson's disease patients and controls.** *Journal of Medical Genetics*, 2008;45:43-6
140. Kreisler A, Mastain B, Tison F, Fénelon G, Destée A. **Multi-infarct disorder presenting as corticobasal degeneration (DCB): vascular pseudo-corticobasal degeneration?** *Revue Neurologique (Paris)*, 2007; 163:1191-9.
141. Lesage S, Lohmann E, Tison F, Durif F, Dürr A, Brice A. **Gene symbol: PARK2. Disease: Parkinsonism, juvenile, autosomal recessive.** *Human Genetics*, 2008; 123:114.
142. Lambrecq V, Krim E, Meissner W, Guehl D, Tison F. **Stimulation cérébrale profonde du pallidum interne dans l'atrophie multisystématisée** *Revue Neurologique (Paris)*, 2008;164:398-402.
143. Tison F. **Traitement des phases tardives de la maladie de Parkinson** *Revue Neurologique (Paris)*, 2008;164 Suppl 2:F85-8.
144. du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, Guyant-Maréchal L, Forlani S, Jauffret C, Vandenberghe N, N'guyen K, Le Ber I, Devos D, Vincitorio CM, Manto MU, Tison F, Hannequin D, Ruberg M, Brice A, Durr A. **Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.** *Brain*, 2008; 131:1352-61.
145. Flabeau O, Foubert-Samier A, Meissner W, Tison F. **Hearing and seeing: Unusual early signs of Wernicke encephalopathy.** *Neurology*, 2008; 71:694.
146. Ghorayeb I, Bioulac B, Scribans C, Tison F. **Perceived severity of restless legs syndrome across the female life cycle.** *Sleep Medicine*, 2008; 9:799-802.
147. Meissner W, Macia F, Foubert-Samier A, Guyot M, Bussy E, Allard M, Tison F. **Dopamine transporter binding is reduced following disulfiram-induced striatal damage.** *Movement Disorders*, 2009;24:941-943

148. Foubert-Samier A, Kazadi A, Rouanet M, Vital A, Lagueny A, Tison F, Meissner W. **Axonal sensory motor neuropathy in copper-deficient Wilson's disease.** *Muscle and Nerve.*, 2009;40:294-6
149. Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Péchoix S, Brefel-Courbon C, Destée A, Tranchant C, **Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson's disease.** *Journal of Medical Genetics*, 2009; 46:458-64
150. Vital A, Fernagut PO, Canron MH, Joux J, Bezard E, Martin-Negrier ML, Vital C, Tison F. **The nigrostriatal pathway in Creutzfeldt-Jakob disease.** *Journal of Neuropathol Experimental Neurology*, 2009;68:809-15.
151. Ghorayeb I, Tison F. **Epidemiologie du syndrome des jambes sans repos.** *Revue Neurologique (Paris)*, 2009;165:641-9.
152. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I. **Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model.** *Experimental Neurology*, 2009; 219:574-82.
153. Flabeau O, Meissner W, Foubert A, Tison F. **Opsoclonus myoclonus syndrome in the context of salmonellosis".** *Movement Disorders*, 2009; 24:2306-8.
154. Nadjar A, Berton O, Guo S, Leneuve P, Dovero S, Diguët E, Tison F, Zhao B, Holzenberger M, Bezard E. **IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP.** *Neurobiology of Aging*, 2009; 30:2021-30.
155. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I. **Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.** *Exp Neurol*. 2009; 219:574-82.
156. Perez F, Helmer C, Dartigues JF, Auriacombe S, Tison F. **A 15-year population-based cohort study of the incidence of Parkinson's Disease and dementia with Lewy bodies in an elderly French cohort.** *Journal of Neurology Neurosurgery and Psychiatry*, 2010, 81:742-6.
157. Lesage S, Condroyer C, Lohman E, Troiano A, Tison F, Viallet F, Damier P, Tranchant C, Vidhaillet M, Ouvrard-Hernandez AM, Dürr A, Brice A; for the French Parkinson's Disease Genetics Study Group (FPDGSG). **Follow-up study of the GIGYF2 gene in French families with Parkinson's disease.** *Neurobiology of Aging*, 2011, 32: 548.e9-18.
158. Perez F, Helmer C, Dartigues JF, Auriacombe S, Tison F. **A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort.** *Journal of Neurology Neurosurgery and Psychiatry* 2010;81:742-6.
159. Meissner WG, Vital A, Ghorayeb I, Guehl D, Tison F. **Dyspnea as first sign of autonomic failure in postmortem confirmed multiple system atrophy.** *Movement Disorders*, 2010; 25:1997-8.
160. Ghorayeb I, Tison F. **Le syndrome des jambes sans repos** *Presse Med.* 2010;39:564-70.
161. Damon-Perrière N, Tison F, Meissner WG. **L'atrophie Mulisystématisée.** *Psychol Neuropsychiatr Vieil.* 2010; 8:179-91.
162. Farid K, Meissner WG, Samier-Foubert A, Barret O, Menegon P, Rouanet F, Fernandez P, Orgogozo JM, Allard M, Tison F, Sibon I. **Normal cerebrovascular reactivity in Stroke-like Migraine Attacks after Radiation Therapy syndrome.** *Clinical Nuclear Medicine*, 2010;35:583-5.
163. Fernagut PO, Barraud Q, Bezard E, Ghorayeb I, Tison F. **Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism.** *Neurology Research*, 2010;32:1050-3.
164. Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. **Motor activation in multiple system atrophy and Parkinson disease: a PET study.** *Neurology*, 2010; 75:1174-80.

165. Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhelef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK; EMSA-SG. **Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.** *Movement Disorders*, 2010; 15:2604-12.
166. Dujardin K, Dubois B, Tison F, Durif F, Bourdeix I, Péré JJ, Duhamel A; **EXECUTIVE study group.** **Parkinson's disease dementia can be easily detected in routine clinical practice.** *Movement Disorders*. 2010;25:2769-76
167. Barraud Q, Obeid I, Aubert I, Barrière G, Contamin H, McGuire S, Ravenscroft P, Porras G, Tison F, Bezard E, Ghorayeb I. **Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate.** *PLoS One*. 2010;5:e13306.
168. Leger F, Fernagut PO, Cannon MH, Léoni S, Vital C, Tison F, Bezard E, Vital A. **Protein aggregation in the aging retina.** *Journal of Neuropathology and Experimental Neurology*, 2011;70:63-8.
169. Tison F, Le Masson G. **Parkinson disease, L-dopa, and neuropathy: did we miss something?** *Neurology*, 2011;77:1938-9.
170. Gantenbein AR, Damon-Perrière N, Bohlender JE, Chauveau M, Latxague C, Miranda M, Jung HH, Tison F. **Feeding dystonia in McLeod syndrome.** *Movement Disorders*, 2011;26:2123-6.
171. Chauveau M, Damon-Perriere N, Latxague C, Spampinato U, Jung H, Burbaud P, Tison F. **Head drops are also observed in McLeod syndrome.** *Movement Disorders*, 2011;26:1562-3.
172. Rué M, Lüdecke HJ, Sibon I, Richez C, Taine L, Foubert-Samier A, Arveiler B, Schaefferbeke T, Lacombe D, Tison F, Goizet C. **Rheumatologic and neurological events in an elderly patient with tricho-rhino-phalangeal syndrome type I.** *European Journal of Medical Genetic*, 2011;54:e405-8.
173. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E. **Priorities in Parkinson's disease research.** *Nature Reviews Drug Discovery*, 2011;10:377-93.
174. Meissner W, Tison F. **Acquired hepatocerebral degeneration.** *Handbook of Clinical Neurology*, 2011;100:193-7.
175. Fantin M, Morari M, Tison F, Fernagut PO. **NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid.** *Neurology Research*, 2011;33:444-7.
176. Marelli C, van de Leemput J, Johnson JO, Tison F, Thauvin-Robinet C, Picard F, Tranchant C, Hernandez DG, Huttin B, Boulliat J, Sangla I, Marescaux C, Brique S, Dollfus H, Arepalli S, Benatru I, Ollagnon E, Forlani S, Hardy J, Stevanin G, Dürr A, Singleton A, Brice A. **SCA15 due to large ITPR1 deletions in a cohort of 333 white families with dominant ataxia.** *Archives of Neurology*, 2011;68:637-43
177. Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O. **The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension.** *Movement Disorders*, 2011;26:1985-92.
178. Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, Vidailhet M, Mellick GD, Lohmann E, Durif F, Pollak P, Damier P, Tison F, Silburn PA, Tzourio C, Forlani S, Lioriot MA, Giroud M, Helmer C, Portet F, Amouyel P, Lathrop M, Elbaz A, Durr A, Martinez M, Brice A; French Parkinson's Disease Genetics Study Group. **Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population.** *Human Molecular Genetics*, 2011;20:615-27.
179. Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A. **Assessment of quality of life with the multiple system atrophy health-related quality of life scale.** *Movement Disorders* 2012; 27:1574-7.
180. Tison F. **Can long-term levodopa treatment induce neuropathy in PD?** *Movement Disorders*, 2012;27:474.

181. Fernagut PO, Vital A, Canron MH, Tison F, Meissner WG. **Ambiguous mechanisms of dysphagia in multiple system atrophy.** *Brain*, 2012;13:e205.
182. Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, Dartigues JF, Tison F. **Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort.** *Neurology*, 2012; 79:1615-21.
183. Perez F, Helmer C, Foubert-Samier A, Auriacombe S, Dartigues JF, Tison F. **Risk of dementia in an elderly population of Parkinson's disease patients: a 15-year population-based study.** *Alzheimers and Dementia* 2012; 8:463-9.
184. Fernagut PO, Tison F. **Animal models of multiple system atrophy.** *Neuroscience*, 2012; 211:77-82.
185. Vital A, Latour P, Sole G, Ferrer X, Rouanet M, Tison F, Vital C, Goizet C. **A French family with Charcot-Marie-Tooth disease related to simultaneous heterozygous MFN2 and GDAP1 mutations.** *Neuromuscular Disorders*, 2012; 22:735-41
186. Foubert-Samier A, Maurice S, Hivert S, Guelh D, Rigalleau V, Burbaud P, Cuny E, Meissner W, Tison F. **A long-term follow-up of weight changes in subthalamic nucleus stimulated Parkinson's disease patients.** *Revue Neurologique (Paris)*. 2012; 168:173-6.
187. Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, Tison F, Merello M, Rascol O; COPARK Study Group. **Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort.** *European Journal of Neurology*, 2012;19:28-37
188. Damon-Perrière N, Foubert-Samier A, De Cock VC, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison F, Meissner WG. **Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time.** *Parkinsonism and Related Disorder*. 2012; 18:612-5.
189. Lesage S, Condroyer C, Klebe S, Honoré A, Tison F, Brefel-Courbon C, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. **Identification of VPS35 mutations replicated in French families with Parkinson disease.** *Neurology*. 2012; 78:1449-50
190. Lesage S, Condroyer C, Klebe S, Lohmann E, Durif F, Damier P, Tison F, Anheim M, Honoré A, Viallet F, Bonnet AM, Ouvrard-Hernandez AM, Vidailhet M, Durr A, Brice A; French Parkinson's Disease Genetics Study Group. **EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?** *Neurobiology of Aging*. 2012 ;33:2233.e1-2233.e5.
191. Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, De Cock VC, Rascol O, Tison F, Pavy-Le Traon A. **Assessment of quality of life with the multiple system atrophy health-related quality of life scale.** *Movement Disorders*, 2012;27:1574-7.
192. Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group. **Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.** *Lancet Neurology*, 2012; 11:589-96.
193. Mazère J, Meissner WG, Mayo W, Sibon I, Lamare F, Guilloteau D, Tison F, Allard M. **Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol.** *Radiology*, 2012; 265:537-43
194. Ghorayeb I, Bénard A, Vivot A, Tison F, Burbaud P. **A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome.** *Sleep Medicine*, 2012; 13:1313-6.
195. Apartis E, Blancher A, Meissner WG, Guyant-Maréchal L, Maltête D, De Broucker T, Legrand AP, Bouzenada H, Thanh HT, Sallansonnet-Froment M, Wang A, Tison F, Roué-Jagot C, Sedel F, Charles P, Whalen S, Héron D, Thobois S, Poisson A, Lesca G, Ouvrard-Hernandez AM, Fraix V, Palfi S, Habert MO, Gaymard B, Dussaule JC, Pollak P, Vidailhet M, Durr A, Barbot JC, Gourlet V, Brice A, Anheim M. **FXTAS: new insights and the need for revised diagnostic criteria.** *Neurology*, 2012; 79:1898-907.

196. Krismer F, Seppi K, Tison F, Sampaio C, Zangerl A, Peralta C, Yekhlef F, Ghorayeb I, Ory-Magne F, Galitzky M, Bozi M, Scaravilli T, Colosimo C, Geser F, Rascol O, Poewe W, Quinn NP, Wenning GK; European Multiple System Atrophy Study Group. **The Unified Multiple System Atrophy Rating Scale: intrarater reliability.** *Movement Disorders*, 2012; 27:1683-5.
197. Tison F, Nègre-Pagès L, Meissner WG, Dupouy S, Li Q, Thiolat ML, Thiollier T, Galitzky M, Ory-Magne F, Milhet A, Marquine L, Spampinato U, Rascol O, Bezard E. **Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.** *Parkinsonism and Related Disorders*, 2013;19:416-21.
198. Meissner WG, Foubert-Samier A, Dupouy S, Debs R, Gerdelat-Mas A, Cochen De Cock V, Schrag A, Rascol O, Tison F, Pavy-Le Traon A. **Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL).** *Revue Neurologique (Paris)*. 2013; 169:53-8.
199. Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W, European Multiple System Atrophy Study Group. **The natural history of multiple system atrophy: a prospective European cohort study.** *Lancet Neurology*, 2013;12:264-74.
200. Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbäumer G, Charfi R, Klein C, Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC; French Parkinson's Disease Genetics Study Group; International Parkinson's Disease Genomics Consortium (IPDGC). **The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.** *Journal of Neurology Neurosurgery and Psychiatry*, 2013;84:666-73.
201. Duval F, Flabeau O, Razafimahefa J, Spampinato U, Tison F. **Encephalopathy associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.** *Movement Disorders*, 2013; 28:1464.
202. Meissner WG, Fernet M, Couturier J, Hall J, Laugé A, Henry P, Stoppa-Lyonnet D, Tison F. **Isolated generalized dystonia in biallelic missense mutations of the ATM gene.** *Movement Disorders*, 2013; 28:1897-9.
203. Spampinato U, Debruxelles S, Rouanet M, Lafoucrière D, Bader B, Danek A, Tison F, Goizet C. **Head drops are also observed in advanced Huntington disease.** *Parkinsonism and Related Disorders*, 2013;19:569-70.
204. Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut PO. **Reinforcing properties of Pramipexole in normal and parkinsonian rats.** *Neurobiology of Disease*, 2013;49:79-86.
205. Miquel M, Spampinato U, Latxague C, Aviles-Olmos I, Bader B, Bertram K, Bhatia K, Burbaud P, Burghaus L, Cho JW, Cuny E, Danek A, Foltynie T, Garcia Ruiz PJ, Giménez-Roldán S, Guehl D, Guridi J, Hariz M, Jarman P, Kefalopoulou ZM, Limousin P, Lipsman N, Lozano AM, Moro E, Ngy D, Rodriguez-Oroz MC, Shang H, Shin H, Walker RH, Yokochi F, Zrinzo L, Tison F. **Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis.** *PLoS One*. 2013;8:e79241.
206. Mazere J, Meissner WG, Sibon I, Lamare F, Tison F, Allard M, Mayo W. **[(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6).** *Neuroimage Clinical*, 2013;3:212-7.
207. Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Schelosky L, Tison F, Rascol O. **Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.** *JAMA Neurology*, 2014;71:884-90.
208. Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O, Poli SM. **The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.** *Movement Disorders*, 2014;29:1074-9.
209. Ghorayeb I, Dupouy S, Tison F, Meissner WG. **Restless legs syndrome in multiple system atrophy.** *Journal of Neural Transmission*, 2014;121:1523-7.

210. Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison E, Meissner WG. **Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.** *Neurobiology of Disease*. 2014; 67:133-9.
211. Rey MV, Perez-Lloret S, Pavy-Le Traon A, Meissner WG, Tison E, Rascol O. **A cross-sectional study on drug use in multiple system atrophy.** *CNS Drugs*. 2014; 28:483-90.
212. Meissner WG, Flabeau O, Perez P, Taillard J, Marquant F, Dupouy S, Tison E, Philip P, Ghorayeb I. **Accuracy of portable polygraphy for the diagnosis of sleep apnea in multiple system atrophy.** *Sleep Medicine*, 2014; 1:476-9.
213. Vital A, Meissner WG, Canron MH, Martin-Negrier ML, Bezard E, Tison E, Vital C. **Intra-axonal protein aggregation in the peripheral nervous system.** *Journal of Peripheral Nervous System*, 2014; 19:44-9.
214. Flabeau O, Meissner WG, Ozier A, Berger P, Tison E, Fernagut PO. **Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy.** *Movement Disorders*, 2014;29:388-95.
215. Tison E, Meissner WG. **Movement disorders in 2013: diagnosing and treating PD-the earlier the better?** *Nature Reviews Neurology*, 2014;10:65-6.
216. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison E, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. **Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.** *Neurology*, 2014;82:300-7.
217. Delva F, Auriacombe S, Letenneur L, Foubert-Samier A, Bredin A, Clementy A, Latxague C, Puymirat E, Ballan G, Delabrousse-Mayoux JP, Glénisson L, Mazat L, Spampinato U, Rainfray M, Tison F, Dartigues JF. **Natural history of functional decline in Alzheimer's disease: a systematic review.** *Journal of Alzheimer's disease*, 2014; 40:57-67.
218. Fernagut PO, Meissner WG, Biran M, Fantin M, Bassil F, Franconi JM, Tison E. **Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy.** *Synapse*. 2014; 68:98-106.
219. Hyacinthe C, Barraud Q, Tison E, Bezard E, Ghorayeb I. **D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.** *Neurobiology of Disease*, 2014;63:20-4.
220. Cubizolle S, Damon-Perrière N, Dupouy S, Foubert-Samier A, Tison E. **Parkinson's disease, L-Dopa and "express" saccades: superior colliculus dyskinesias?** *Clinical Neurophysiology*, 2014 125:647-8.
221. Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison E, Negre-Pages L. **Falls in ambulatory non-demented patients with Parkinson's disease.** *Journal of Neural Transmission*, 2015 Apr 7. [Epub ahead of print]
222. Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison E, Houeto JL, Krack P, Durif F. **International validation of a behavioral scale in Parkinson's disease without dementia.** *Movement Disorders*, 2015;30:705-13.
223. Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison E, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group. **Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.** *Brain*, 2015; 138:1271-83.
224. Legati A, Donatella Giovannini D, Nicolas G, López-Sánchez U, Quintáns B, Oliveira J, Sears RL, Marisa Ramos EM, Spiteri E, Sobrido MJ, Carracedo A, Castro-Fernández C, Cubizolle S, Fogel BL, Goizet C, Jen JC, Kirdlar S, Lang AE, Miedzybrodzka Z, Mitarnun W, Paucar M, Paulson H, Pariente J, Richard AC, Salins NS, Simpson SA, Striano P, Svenningsson P, Tison E, Unni VK, Vanakker O, Wessels MW, Wetchaphanphesat S, Yang M, Boller F, Campion D, Hannequin D, Sitbon M, Geschwind DH, Battini JL, Giovanni Coppola G. **Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export.** *Nature Genetics*, 2015; doi:10.1038/ng.3289

225. Lesage S, Bras J, Cormier-Dequaire F, Condroyer C, Nicolas A, Darwent L, Guerreiro R, Majounie E, Federoff M, Heutink P, Wood NW, Gasser T, Hardy J, Tison F, Singleton AB, Brice A. **Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson's disease.** *Neurology* 2015, in press

226. Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG; European MSA Study Group. **New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.** *Journal of Neurology Neurosurgery and Psychiatry*, 2015 May 14. pii: jnnp-2014-309999. doi: 10.1136/jnnp-2014-309999. [Epub ahead of print]

Publications in the name of a study group (n= 54) :

1. de Rijk M.C., Tzourio C., Breteler M.M.B., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Berran J.M., Alperovitch A., Rocca W.A. for the EUROPARKINSON Study Group. **Prevalence of parkinsonism and Parkinson's disease in Europe : the EUROPARKINSON collaborative study.** *Journal of Neurology Neurosurgery and Psychiatry*, 1997; 62 : 10-15.

2. The French Parkinson's disease study group. **Apolipoprotein E genotype in familial Parkinson's disease.** *Journal of Neurology Neurosurgery and Psychiatry*, 1997; 63:394-395.

3. Tzourio C., Rocca W.A., Breteler M.M.B., Amaducci L., Dartigues J.F., Lopez-Pousa S., Manubens-Berran J.M., Alperovitch A., for the EUROPARKINSON Study Group. **Smoking and Parkinson's disease : an age-dependant risk effect ?** *Neurology*, 1997; 49 : 1267-1272.

4. The French Parkinson's Disease Genetics Study Group. **Alpha-Synuclein gene and Parkinson's disease.** *Science*, 1998 ; 279: 1116-1117

5. Tassin J. Dürr A, de Broucker T et al. and the French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. **Chromosome 6-linked autosomal recessive early-onset parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family.** *American Journal of Human Genetics*, 1998 ; 63: 88-94

6. Lücking CB, Abbas N, Dürr A, Bonifati V, Bonnet AM, De Broucker T, De Michele G, Wood NW, Agid Y, Brice A for the European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. **Homogenous deletions in parkin gene in European in North-African families with autosomal recessive juvenile parkinsonism.** *Lancet*, 1998, 352: 1355-56.

7. Lücking CB, Abbas N, Dürr A, Bonifati V, Bonnet AM, de Broucker T, De Michele G, Wood NW, Agid Y, Brice A. **Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.** *Lancet*. 1998 24;352(9137):1355-6

8. The French Tolcapone Study Group. **Efficacy and tolerability of Tolcapone compared with bromocriptine in levodopa-treated parkinsonism patients.** *Movement Disorders*, 1999; 14: 38-44.

9. The French Clozapine Parkinson Study Group (Steering committee: Pollack P., Destée A., Tison F., Péré J.J., Bordeix I.). **Clozapine in drug-induced psychosis in Parkinson's disease.** *Lancet*, 1999, 253: 2041-2042.

10. Almqvist E., Bloch M., Brinkman R., Craufurd D, Hayden M.R on the behalf of an International Huntington disease collaborative group. **A worldwide assessment of the frequency of suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease.** *American Journal of Human Genetics*, 1999; 64: 1293-1304.

11. Abbas N, Lücking CB, Ricard S, Dürr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Bohme GA, Pradier L, Wood NW, Filla A, Meco G, Deneffe P, Agid Y, Brice A. **A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.** *Human Molecular Genetics*, 1999, 8:567-74.

12. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Deneffe P, Wood NW, Agid Y, Brice A. **Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group.** *New England Journal Medicine*, 2000;34:1560-7.

13. Bonifati V, De Michele G, Lucking CB, Durr A, Fabrizio E, Ambrosio G, Vanacore N, De Mari M, Marconi R, Capus L, Breteler MM, Gasser T, Oostra B, Wood N, Agid Y, Filla A, Meco G, Brice A; Italian PD Genetics Study Group, French PD Genetics Study Group, European Consortium on Genetic Susceptibility in PD. **The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.** *Neurological Sciences*, 2001, 22:51-2.
14. Periquet M, Lucking C, Vaughan J, Bonifati V, Durr A, De Michele G, Horstink M, Farrer M, Illarioshkin SN, Pollak P, Borg M, Brefel-Courbon C, Deneffe P, Meco G, Gasser T, Breteler MM, Wood N, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group. The European Consortium on Genetic Susceptibility in Parkinson's Disease. **Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.** *American Journal of Human Genetics*, 2001; 68:617-26.
15. Rawal N, Periquet M, Durr A, de Michele G, Bonifati V, Teive HA, Raskin S, Guimaraes J, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. **Exclusion of the Nurr1 gene in autosomal recessive Parkinson's disease.** *Journal of Neurology*, 2002; 249:1127-9.
16. West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze JF, Maraganore D, Levey A, Wood N, Durr A, Hardy J, Brice A, Farrer M; French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility on Parkinson's Disease. **Complex relationship between Parkin mutations and Parkinson disease.** *American Journal of Medical Genetics*, 2002 8; 114(5):584-91. *Erratum in: Am J Med Genet* 2002, 8;114:992.
17. Rawal N, Periquet M, Lohmann E, Lucking CB, Teive HA, Ambrosio G, Raskin S, Lincoln S, Hattori N, Guimaraes J, Horstink MW, Dos Santos Bele W, Broussolle E, Destee A, Mizuno Y, Farrer M, Deleuze JF, De Michele G, Agid Y, Durr A, Brice A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. **New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism.** *Neurology*, 2003; 60:1378-81.
18. Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G, Ricard S, Teive H, Fraix V, Vidailhet M, Nicholl D, Barone P, Wood NW, Raskin S, Deleuze JF, Agid Y, Durr A, Brice A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. **Parkin mutations are frequent in patients with isolated early-onset parkinsonism.** *Brain*, 2003 ;126 :1271-8
19. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. **How much phenotypic variation can be attributed to parkin genotype?** *Annals of Neurology*, 2003; 54:176-85.
20. Thobois S, Ribeiro MJ, Lohmann E, Durr A, Pollak P, Rascol O, Guillouet S, Chapoy E, Costes N, Agid Y, Remy P, Brice A, Broussolle E; French Parkinson's Disease Genetics Study Group. **Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study** *Archives of Neurology*, 2003; 60:713-8.
21. Ibanez P, De Michele G, Bonifati V, Lohmann E, Thobois S, Pollak P, Agid Y, Heutink P, Durr A, Brice A; French Parkinson's Disease Genetics Study Group. Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism. *Neurology*, 2003;61:1429-31
22. Ibanez P, Lohmann E, Pollak P, Durif F, Tranchant C, Agid Y, Durr A, Brice A and the French Parkinson's Disease Genetics Study Group. **Absence of NR4A2 exon 1 mutations in 108 families of autosomal dominant Parkinson's disease.** *Neurology*, 2004; 62:2133-4 .
23. Martinez M, Brice A, Vaughan JR, Zimprich A, Breteler MM, Meco G, Filla A, Farrer MJ, Betard C, Hardy J, De Michele G, Bonifati V, Oostra B, Gasser T, Wood NW, Durr A; French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. **Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.** *Journal of Medical Genetics*, 2004;41:900-7
24. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, Brice A; French Parkinson's Disease Genetics Study Group. **LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century.** *American Journal of Human Genetics*, 2005; 77:330-2.

25. Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Illig T, Wichmann HE, Wenning GK, Wood NW, Gasser T; European Multiple System Atrophy Study Group. **The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group.** *Brain*, 2005; 128:1855-60.
26. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A; French Parkinson's Disease Genetics Study Group. **LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.** *New England Journal of Medicine*, 2006; 354:422-3.
27. Ibanez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M, Agid Y, Durr A, Brice A; French Parkinson's Disease Genetics Study Group. **Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.** *Brain*, 2006;12:686-94
28. S, Leclere L, Lohmann E, Borg M, Ruberg M, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. **Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.** *Neurodegenerative Diseases*, 2007; 4:195-8.
29. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. **Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.** *Archives of Neurology*, 2008;65:577-83.
30. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium. **Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.** *Lancet Neurology*, 2008; 7:583-90.
31. Lesage S, Belarbi S, Troiano A, Condroyer C, Hecham N, Pollak P, Lohman E, Benhassine T, Ysmail-Dahlouk F, Dürr A, Tazir M, Brice A; French Parkinson's Disease Genetics Study Group. **Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?** *Neurology*, 2008; 71:1550-2.
32. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group, Roos RA. **Weight loss in Huntington disease increases with higher CAG repeat number.** *Neurology*, 2008; 71:1506-13.
33. Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F, Destée A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. **Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms.** *Archives of Neurology*, 2009; 66:102-8.
34. Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Brice A; French Parkinson's Disease Genetics Study Group. **A multidisciplinary study of patients with early-onset PD with and without parkin mutations.** *Neurology*, 2009;72:110-6.
35. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. **A double-blind, delayed-start trial of rasagiline in Parkinson's disease.** *New England Journal of Medicine*, 2009; 361:1268-78.
36. Ardouin C, Chéreau I, Llorca PM, Lhommée E, Durif F, Pollak P, Krack P; groupe évaluation comportementale de la maladie de Parkinson. **Evaluation des comportements hypo- et hyperdopaminergiques dans la maladie de Parkinson.** *Revue Neurologique (Paris)*, 2009; 165:845-56.
37. Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JP; Genetic Epidemiology of Parkinson's Disease (GEOPD) Consortium. **Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study.** *American Journal of Medical Genetics B Neuropsychiatr Genet*, 2010; 153B:220-8.

38. Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, Lin JJ, Lynch T, Mellick GD, de Nigris F, Opala G, Prigione A, Quattrone A, Ross OA, Satake W, Silburn PA, Tan EK, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM; Genetic Epidemiology of Parkinson's disease consortium. **A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease.** *Neurobiology of Aging*. 2011; 32:548.e9-18
39. Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, Bar-Shira A, Belarbi S, Hecham N, Pollak P, Ouvrard-Hernandez AM, Bardien S, Carr J, Benhassine T, Tomiyama H, Pirkevi C, Hamadouche T, Cazeneuve C, Basak AN, Hattori N, Dürr A, Tazir M, Orr-Urtreger A, Quintana-Murci L, Brice A; French Parkinson's Disease Genetics Study Group. **Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.** *Human Molecular Genetics*, 2010;19:1998-2004
40. Troiano AR, Elbaz A, Lohmann E, Belarbi S, Vidailhet M, Bonnet AM, Lesage S, Pollak P, Cazeneuve C, Borg M, Feingold J, Dürr A, Tazir M, Brice A; French Parkinson Disease Genetic Study Group. **Low disease risk in relatives of north african lrrk2 Parkinson disease patients.** *Neurology*, 2010;75:1118-9.
41. Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honoré A, Rivaud S, Vidailhet M, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. **Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.** *Human Molecular Genetics*, 2011;20:202-10
42. Lesage S, Condroyer C, Hecham N, Anheim M, Belarbi S, Lohman E, Viallet F, Pollak P, Abada M, Dürr A, Tazir M, Brice A; French Parkinson Disease Genetic Group. **Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa.** *Neurology*, 2011;76:301-3.
43. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW. **Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.** *Lancet*, 2011;377:641-9.
44. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyrtzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilarinho-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. **Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.** *Lancet Neurology*, 2011;10:898-908.
45. Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. **Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.** *Movement Disorders*, 2012;27:439-42
46. Mittag F, Büchel F, Saad M, Jahn A, Schulte C, Bochdanovits Z, Simón-Sánchez J, Nalls MA, Keller M, Hernandez DG, Gibbs JR, Lesage S, Brice A, Heutink P, Martinez M, Wood NW, Hardy J, Singleton AB, Zell A, Gasser T, Sharma M; International Parkinson's Disease Genomics Consortium. Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. *Human Mutations*, 2012;33:1708-18.
47. Holmans P, Moskvina V, Jones L, Sharma M; International Parkinson's Disease Genomics Consortium, Vedernikov A, Buchel F, Saad M, Bras JM, Bettella F, Nicolaou N, Simón-Sánchez J, Mittag F, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stefánsson H, Majamaa K, Gasser T, Heutink P, Wood NW, Martinez M, Singleton AB, Nalls MA, Hardy J, Morris HR, Williams NM. **A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease** *Human Molecular Genetics*, 2013; 22:1039-49.
48. Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, Pieri L, Mадiona K, Dürr A, Melki R, Verny C, Brice A; French Parkinson's Disease Genetics Study Group. **G51D α -synuclein mutation causes a novel parkinsonian-pyramidal syndrome.** *Annals of Neurology*. 2013; 73:459-71

49. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. **Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.** *Nature Genetics*, 2014; 49:989-93.

50. Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbstaël E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson's Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR. **Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.** *Proceeding of the National Academy of Sciences U S A*, 2014; 111:2626-31

51. Dong J, Gao J, Nalls M, Gao X, Huang X, Han J, Singleton AB, Chen H; International Parkinson's Disease Genomics Consortium (IPDGC). **Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.** *Neurobiology of Aging*. 2014; 35:1512.e5-10.

52. Nalls MA, Saad M, Noyce AJ, Keller MF, Schrag A, Bestwick JP, Traynor BJ, Gibbs JR, Hernandez DG, Cookson MR, Morris HR, Williams N, Gasser T, Heutink P, Wood N, Hardy J, Martinez M, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC). **Genetic comorbidities in Parkinson's disease.** *Human Molecular Genetics*, 2014;23:831-41.

53. Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, Plagnol V, Gibbs JR, Schulte C, Pankratz N, Sutherland M, Bertram L, Lill CM, DeStefano AL, Faroud T, Eriksson N, Tung JY, Edsall C, Nichols N, Brooks J, Arepalli S, Pliner H, Letson C, Heutink P, Martinez M, Gasser T, Traynor BJ, Wood N, Hardy J, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Disease meta-analysis consortium. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. *Neurobiology of Aging*, 2015;36:1605.e7-5.

54. Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. **Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.** *JAMA Neurology*, 2015 Jan;72(1):88-95.

Book chapters:

1. Henry P, Tison F., Traore M. **Hypotension orthostatique du sujet âgé.** In : *Système nerveux végétatif du sujet âgé*, Serratrice G. (ed) GNSL, 1988 : 39-46.

2. Lebrun-Grandié P., Kien P., Tison F., Henry P., Caille J.M., Bioulac B. **A magnetic resonance imaging evaluation of movement disorders.** In : *Neural mechanisms in disorders of movement*, Crossman A.R, Sambrook M.A. (eds). John Libbey, London, 1989 : 413-423.

3. Henry P., Brochet B., Tison F. **Système nerveux autonome et maladie migraineuse.** In : *Actualités Neuromusculaires-Système nerveux végétatif, Acquisitions récentes*. Serratrice G., Pelissier JF, Pouget J., Blin O. (eds), 1990 : 219-224.

4. Henry P., Brochet B., Rossazza M., Tison F. **Système nerveux végétatif et douleurs vasculaires céphaliques.** In : *GRECS : La douleur vasculaire-La neuroplasticité*. Editions Sandoz, 1991 : 41-48.

5. Tison F., Bloch B. **Les récepteurs à la dopamine : données récentes.** In : *Actualités dans la maladie de Parkinson*. Editions Schering, 1993 : 12-14.

6. Henry P, Tison F. **Aspects vasculaires de la migraine.** In : *GRECS : Posture et locomotion chez le sujet âgé-Physiopathologie de la migraine*. Editions Sandoz, 1996 : 33-39.

7. Tison F., Quinn N. **L'atrophie multisystématisée.** In : *Encyclopédie Médico-Chirurgicale, Neurologie.* Elsevier, Paris, 17-062-D-10, 1996, 10 p.
 8. Henry P., Tison F., Brochet B. **Céphalées, algies de la face.** In : *Neurologie*, Serratrice G., Autret A. (eds). Ellipses, Aupel/Uref, 1996 : 646-648.
 9. Tison F. **Traitement des dystonies de l'adolescent et de l'adulte jeune dans le cadre de l'IMOC.** In : *L'infirmité motrice cérébrale*, Amiel-Tison C. Masson, 1ere édition 1997 : 276-277. Et In : *L'infirmité motrice cérébrale*, Amiel-Tison C. Masson, 2^{ème} édition 2004 : 280-282.
 10. Henry P., Tison F., Brochet B. **Céphalées et algies vasculaires de la face.** In : *Douleurs.* Brasseur L., Chauvin M., Guilbaud G.(eds). Maloine, Paris, 1997: 503-512.
 11. Tison F. **Other causes of Parkinsonism.** In : *Baillière's Clinical Neurology. Parkinsonism*, Quinn N.P. (ed). Baillières-Tindall, London, Vol. 6, n°1, 1997 : 205-218.
 12. Tison F. **Maladie de Parkinson et syndromes parkinsoniens.** In : *Prise en charge de la maladie de Parkinson.* Masson, 1998, 41-58
 13. Tison F. **Les dyskinésies induites dans la maladie de Parkinson : Perspectives historiques** In : *les dyskinésies induites par la L-dopa dans la maladie de Parkinson.* Destée A, Rascol O, Vidailhet M (eds). Acanthe, Masson 2001 : 1-7.
 14. Goizet C., Ballan G, Tison F. **Atrophies (dégénérescences) cérébelleuses tardives.** In : *Encyclopédie Médico-Chirurgicale, Neurologie.* Elsevier, Paris, 17-063-D-10, 2002, 12 p.
 15. Tison F. **The differential diagnosis of neuroacanthocytosis : an overview.** In : *Neuroacanthocytosis syndromes.* Danek A (ed). Springer Verlag 2005 : 15-21
 16. Ghorayeb I, Stefanova N, Fernagut PO, Wenning GK, Tison F. **Double-lesion animal models of Multiple System Atrophy.** In : *Animal Models of Movement Disorders. LeDoux M (ed)*, Elsevier Academic Press 2005 : 571-584.
 17. Chrysostome V, Tison F. **Epidémiologie de la Maladie de Parkinson.** In : *La maladie de Parkinson.* Defebvre L, Verin M. Monographies de Neurologie. Masson 2005 : 3-6
 18. Tison F., Gatterie M. **Effet de la stimulation dopaminergique sur troubles de la déglutition dans la maladie de parkinson.** In : *Troubles de la déglutition et de la parole dans la maladie de Parkinson.* Ozsancak C, Auzou P (eds). Solal 2005, 313-321
 19. Tison F., Foubert Sanier. **Maladie de Parkinson et mouvements anormaux** *Traité de Médecine hospitalière.* Grünfeld JP ed. Médecine Sciences Flammarion 2006 : 906-912.
 20. Krystkowiak P, Tison F., Bonnet AM. **Echelles et questionnaires dans la Maladie de Parkinson.** In : *EMC(Elsevier Masson SAS, Paris), Neurologie*, 17 035-A683. 2006
 21. Ghorayeb I, Tison F. **Epidémiologie et génétique.** In : *Le syndrome des jambes sans repos.* Krieger J ed. John Libbey Eurotext 2006.
 22. Tison F (sous la direction de) **Les syndromes parkinsoniens atypiques et secondaires.** Masson Acanthes, 2006
 23. Tison, F., Fenelon G. **Qu'est ce qu'un syndrome Parkinsonien atypique.** In : *Les syndromes parkinsoniens atypiques et secondaires, Tison F. ed..* Masson Acanthes, 2006 : 1-3
- Editor of : Les syndromes parkinsoniens atypiques et secondaires, Tison F. ed.. Masson Acanthes, 2006**
24. Chrysostome V, Tison F. **Syndromes Parkinsoniens atypiques « primaires » : épidémiologie.** In: *Les syndromes parkinsoniens atypiques et secondaires, Tison F. ed..* Masson Acanthes, 2006 : 9-22
 25. Krim E, Tison F. **L'atrophie multisystématisée.** In : *Les syndromes parkinsoniens atypiques et secondaires,* Tison F. ed. Masson Acanthes, 2006 : 144-166

26. Fenelon G., Tison F. **Les syndromes parkinsoniens vasculaires.** In : *Les syndromes parkinsoniens atypiques et secondaires*, Tison F. ed. Masson Acanthes, 2006 . 249-261
27. Ghorayeb I, Dolenc-Groselj L, Kkobal J, Pollmächer T, Danek A, Tison F. **Sleep disorders in Neuroacanthocytosis.** In : *Walker RH, Saiki S, Danek A. Neuro-acanthocytosis syndroms II* . Springer –Verlag 2008 (Berlin Heidelberg) : 249-255
28. Krim E, Tison F. **L’atrophie multisystématisée.** In : *EMC(Elsevier Masson SAS, Paris), Neurologie*, 17 062 D010. 2006 et 2008
29. Meissner W., Tison F. **Acquired hepatocerebral degeneration.** In : *Handbook of Clinical Neurology. Movement Disorders, Section 1, Chap 11.* Elsevier Science publishers, 2013
30. Meissner W, Tison F, Goizet C. **Atrophies (dégénérescences) cérébelleuses tardives.** In : *EMC (Elsevier Masson SAS, Paris), Neurologie*, 17-066-A-20, 2011
31. Spampinato U, Tison F. **Depression et maladie de Parkinson.** In : *EMC (Elsevier Masson SAS, Paris), Neurologie*, 17-062-A-13, 2012
32. Foubert-Samier A, Meissner W, Tison F. **L’atrophie multisystématisée.** In : *EMC (Elsevier Masson SAS, Paris), Neurologie*, 17-062-D-10, 2015
33. Chrysostome V, Tison F. **Epidémiologie de la Maladie de Parkinson.** In : *La maladie de Parkinson.* Defebvre L, Verin M. Monographies de Neurologie. Masson 2015 : *in press*
34. Meissner W., Tison F. Multiple systeme atrophy. In: *Parkinson’s disease and Movement Disorders 3rd Edition.* Tolosa and Jankovic eds, Wiliams and Wilkins, 2015, *in press*
35. Tison F. Troubles cognitifs dans la dégénérescence corticobasale. In : *Les démences.* B Dubois ed, Masson 2015 *in press*